Search clinical trials for: Respiratory syncytial virus (RSV) infection

Total 99368 results

MedImmune LLC

Completed

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
ReiThera Srl

Completed

RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.

Respiratory Syncytial Virus Infections

United Kingdom
Pfizer

Completed

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

RSV

United States
RSV Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19

Sars-CoV-2 Infection

Russian Federation
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Infections, Respiratory Syncytial Virus

Canada
University of Rochester

Active, not recruiting

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

Respiratory Syncytial Virus (RSV)

United States
University of Oxford
Innovative Medicines Initiative; Respiratory syncytial virus consortium in...

Active, not recruiting

Understanding RSV: Severe Disease and the Long Term Consequences

Respiratory Syncytial Virus (RSV)

United Kingdom
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus (RSV)

Belgium
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Respiratory Syncytial Virus (RSV)

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
AbbVie

Completed

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis (SUNRISE)

Respiratory Syncytial Virus (RSV)
RSV Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

SARS-CoV-2 Infection

Russian Federation
National Institute of Allergy and Infectious Diseases...

Recruiting

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Respiratory Syncytial Virus

United States
Enanta Pharmaceuticals, Inc
PPD

Completed

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects (RSVP)

Respiratory Syncytial Virus

United States, New Zealand, Bulgaria, Argentina, Poland, South Africa, Ukraine
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
Dalhousie University
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

Respiratory Syncytial Virus

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP 938 Regimens in Children With RSV (RSVPEDs)

Respiratory Syncytial Virus (RSV)

United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
Novavax

Completed

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Respiratory Syncytial Virus (RSV)

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Respiratory Syncytial Virus Infections

United States, Spain, Canada, Finland, Panama, South Africa, New Zealand, Australia, France
Tatyana Zubkova

Completed

Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years

Respiratory Syncytial Virus Infections

Russian Federation
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
Biota Scientific Management Pty Ltd

Completed

Safety Study of Oral BTA9881 to Treat RSV Infection

Respiratory Syncytial Virus Infections

Australia
MicroDose Therapeutx, Inc

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

Respiratory Syncytial Virus Infections | Drug Safety

United States
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
Pfizer

Completed

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Healthy

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (CORAL)

RSV Immunization

United States
University Hospital, Rouen

Completed

TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit

Influenza | Respiratory Syncytial Viruses

France
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
National Institute of Allergy and Infectious Diseases...

Recruiting

Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

Respiratory Syncytial Virus Infections

United States
Hvivo
GlaxoSmithKline

Completed

RSV Study in Adults 60 to 75 Years of Age

RSV Infection

United Kingdom
Sanofi Pasteur, a Sanofi Company

Recruiting

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)

RSV Immunisation

United States, Argentina, Honduras
MedImmune LLC

Terminated

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Participants Less Than 12 Months of Age With RSV Illness

United States
National Institute of Allergy and Infectious Diseases...

Completed

RSV Challenge in Healthy Adults

Respiratory Syncytial Virus | Respiratory Infections, Acute

United States
EuBiologics Co.,Ltd

Recruiting

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years (EuRSV)

Respiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland

3

Subscribe